0MGB.LSE Genmab
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is 0MGB.LSE undervalued?
Graham numberThe Graham number of Genmab cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genmab fundamental analysis
No fundamental analysis for Genmab yet.
Genmab stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also develop…
Full company profileGenmab financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Genmab annual financial statements (DKK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1.82B | 2.37B | 3.03B | 5.37B | 10.1B | - | - | - |
| Operating Income | 1.05B | 1.34B | 1.38B | 2.64B | 6.31B | - | - | - |
| Net Income | 1.19B | 1.10B | 1.47B | 2.17B | 4.76B | - | - | - |
| Balance Sheet | ||||||||
| Total Assets | 5.24B | 6.60B | 8.46B | 15.1B | 21.1B | - | - | - |
| Total Liabilities | 412M | 331M | 447M | 1.10B | 2.02B | - | - | - |
| Shareholders' Equity | 4.83B | 6.27B | 8.01B | 14.0B | 19.1B | - | - | - |
| Cash & Short-term Investments | 3.92B | 5.42B | 6.11B | 11.0B | 16.1B | - | - | - |
| Total Debt | - | - | - | 155M | 277M | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | 328M | 1.59B | 1.02B | 1.33B | 6.43B | 2.23B | 3.91B | - |
| Capital Expenditure | 33.1M | 88.5M | 72.0M | 79.0M | 307M | 252M | 317M | 0.00 |
| Ratios | ||||||||
| ROE | 24.6% | 17.6% | 18.4% | 15.4% | 24.9% | - | - | - |
| ROA | 22.7% | 16.7% | 17.4% | 14.3% | 22.5% | - | - | - |
| Net Profit Margin | 65.4% | 46.7% | 48.7% | 40.4% | 47.1% | - | - | - |
| Debt to Equity | - | - | - | 0.01x | 0.01x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Genmab dividends
Genmab has not paid dividends in the last 9 fiscal years.
Who owns Genmab
- Insiders 1.12%
- Institutions 47.37%
- Public & others 51.51%
- Free float 55.3M
Genmab company profile
- Company name
- Genmab
- Ticker
- 0MGB.LSE
- ISIN
- DK0010272202
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 3,119
- Fiscal year end
- December
- Address
- Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500
- Phone
- 45 70 20 27 28
- Website
- genmab.com
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Genmab management
10- Dr. Jan G.J. van de Winkel Ph.D.Co-Founder, President & CEO · born 1961
- Mr. Anthony Pagano CPAExecutive VP & CFO · born 1978
- Mr. Rayne WallerExecutive VP & Chief Technical Operations Officer · born 1968
- Mr. Gregory David Emil MuellerExecutive VP, General Counsel & Chief Legal Officer · born 1971
- Mr. Christopher CozicExecutive VP & Chief People Officer · born 1978
- Dr. Martine J. van Vugt Ph.D.Executive VP & Chief Strategy Officer · born 1971
- Mr. Martin SchultzSenior Director, Head of Development Business Partnership & Strategy and Director · born 1975
- Dr. Judith V. Klimovsky M.D.Executive VP & Chief Development Officer · born 1958
- Dr. Tahamtan Ahmadi M.D., Ph.D.Executive VP, Chief Medical Officer & Head of Experimental Medicines · born 1973
- Dr. Mijke Zachariasse Ph.D.VP, Head of Antibody Research Materials & Director · born 1973